Abstract
Introduction
Protocol biopsy is the biopsy that is performed at pre-determined time points after renal transplantation in patients with stable allograft function. It aims to detect subclinical insults to the allograft so that the appropriate early intervention can be done to prolong allograft survival. Recurrence of native disease is common after transplantation. IgA Nephropathy also recurs, with reportedly great variation in the incidence. The variation may be because of difference in duration of follow up and biopsy policy of different transplant centers. Most centers perform biopsy only when patients present proteinuria, hematuria or decline in renal function. This may potentially underestimate the true rate of recurrence. The patients who are clinically asymptomatic but have histological changes in the graft kidneys would remain undiagnosed. For centers which perform routine protocol biopsies, histological recurrence with mesangial IgA deposits and mesangial hypercellularity have been reported in 50-60% of patients. [1, 2] In the presence of clinical symptoms, the recurrence rate has been reported from 13-50%. [3, 4] Graft loss from histologic recurrence have been reported between 1.3% and 16% when there were features of diffuse mesangial proliferative expansion and glomerular sclerosis [5] . One of the latest registry report containing possibly the largest number of IgAN patients has shown the estimated 10-year incidence of graft loss due to recurrence to be 9.7% (CI = 4.7-19.5 %). [5] We performed protocol graft biopsy in all transplant recipients to find out the histological occurrence of IgA nephropathy in asymptomatic patients with normal urine findings and stable graft function.
Materials and Methods

Recipients Selection
This study was done in settings of TU Teaching Hospital. All patients who underwent kidney transplantation between 2071 Kartik and 2072 Ashwin were eligible for enrollment in the study.
Immunosuppressive Protocol
All renal transplant recipients received triple immunosuppressive regimens. They were started on tacrolimus and mycofenolate mofetil two days prior to surgery. Intravenous methylprednisolone was given on the day of surgery, followed by oral prednisolone on subsequent days.
All recipients received induction with rATG on Day 0 and Day 1 post-operatively. The usual dose of rATG was 1mg/kg on each day. However, patients who were highly sensitized received up to 2mg/kg of rATG on each day. Patients with two haploidentical HLA at A, B, DRB1 loci were not prescribed induction with ATG. Tacrolimus was given at the dose of 0.1mg/kg/day. Tacrolimus trough level (C0) level was measured on D1 and D5 after transplantation. It was then measured weekly for the first month. After the first month, it was requested on clinician's discretion. At the time of protocol biopsy, i.e. at six months of renal transplantation, the target level of 6-7ng/ml was aimed. Mycofenolate mofetil was given at the dose of 2 gm per day in divided doses. Recipients were maintained at 5 mg of prednisolone as the continuation dose. Sensitized recipients were maintained at 10 mg as the continuation dose. They were followed up post-operatively on out-patient basis, as per institution protocol.
At six months post transplantation, surveillance graft biopsy was performed in all patients who gave informed written consent.
Recipients Exclusion
Following recipients were excluded: 1. Recipients not consenting to the study 2. Recipients who had proteinuria at six months 3. Recipients who didn't have stable graft function at six months 4. Recipients with acute kidney injury, active infections or urinary tract obstruction Biopsy Protocol Recipients undergoing protocol graft biopsy were admitted a day prior to the procedure. All basic investigations including coagulation parameters and viral serology were sent routinely. Contraindications to biopsy were uniformly ruled out prior to the procedure. 
Discussion
IgA Nephropathy was detected in 12.8% recipients. Unfortunately, no pre-transplant biopsies were performed in these cases. Thus, we couldn't classify them as true recurrence. Ortiz et al reported the histological recurrence of IgAN in almost one-third of the patients after 2 years from transplantation. In a study which reviewed IgAN recurrence in 32 protocol biopsies, recurrence rate was 53%. [2] Another study including 11 biopsies had recurrence rate of 27%. [5] With regards to recurrence, the results are found to be similar in the studies including the patients using modern immunosuppression. In most centers, the suspicion of IgAN recurrence is based on the presence of hematuria, proteinuria or a decline in renal function. In those cases, the recurrence rate was between 12.5 and 50%. [6] Importantly, it was found that 52% of the IgAN recurrences diagnosed by protocol biopsies were not accompanied by proteinuria or hematuria. Thus, protocol biopsies with immunofluorescence analysis constitute an essential tool for the diagnosis of recurrence, even if it is clinically silent [7] . In our study, we were not able to rule out the possibility that IgA deposits were already present in the donors. Autopsy studies from cases without known renal disease report histologic IgANin 4-8%. [8] However, a gradual resolution of IgA deposits is expected to occur within 45 days following transplantation. In a study of 0-h renal biopsies, where 87% of transplants were from living donors, latent mesangial deposition of IgA was present in 16% of its cases. Interestingly, the codeposition of C3 was detected in only 19%. [9] In our study, recurrent IgAN was associated with C3 deposition in all cases. This may suggest that there was already complement activation and therefore potential inflammatory response. Taking into account both the timing of protocol biopsy and the concomitant complement deposition, we do not consider that the IgA deposits were related to persistence of donor IgA deposits in the graft. Use of Mycophenolate mofetil for immunosuppression has been thought to lower incidence of recurrence as opposed to azathioprine-based therapy. However, it could not be verified in a small retrospective study and still needs to be tested in a prospective study. [10] Almost all of our patients were on MMF based therapy, except one who was switched to azathioprine. So, we were not able to make the comparison between the two groups. Three out of six recipients with mesangial IgA deposits were treated with increased doses of prednisolone and mycofenolate mofetil. These were the ones who also exhibited glomerular or interstitial inflammation. All six recipients received cod liver oil and ARB as supportive management. The optimal regimen of immunosuppressive drugs for the treatment of primary IgAN in patients at risk of progression still remains uncertain. [11] The use of calcineurin inhibitors, either in the presence or absence of induction therapy, does not influence the risk of recurrence. When azathioprine and Mycophenolate mofetil (MMF), cyclosporine and tacrolimus, sirolimus and prednisone were compared, there was no difference in the rate of graft loss due to recurrence [12] . A study has reported development of IgAN with nephrotic range of proteinuria in two transplant recipients after conversion from a calcineurin inhibitor based immunosuppression to sirolimus [13] . Use of steroid free or rapid steroid withdrawal regimen hasn't been found to affect the risk of recurrence [14] . Recommended treatment for primary IgAN includes ACE-i or ARB [15] . There have also been case reports of fish oil having a favorable effect in recurrent IgAN, but no studies have been performed to support its routine use [16] .
Safety of Protocol Kidney Biopsy
Use of protocol biopsies has been limited in some centers by concerns over their safety. There are a number of studies that suggest that the biopsy procedure is considerably safe [17, 18] . None of the recipients in our study developed complications related to the procedure. This is in accordance with large studies which reported major complication rate between 0.4 to 1 percent. [8] It is also in accordance with the view that it is ethically justifiable to perform protocol graft kidney biopsies both in clinical trials and routine care.
Conclusion
Our study demonstrates that IgA Nephropathy does occur in patients with stable GFR and without any clinical or laboratory abnormalities. Protocol biopsy is valuable in detection of early histologic abnormalities before onset of clinical manifestations, thus helping in prompt management with aim to prolong the graft survival.
